• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
  • Angion Biomedica, Sinovant Sciences collaborate to develop BB3 biospectrumasia
    November 19, 2018
    Angion is currently developing BB3 in a Phase 3 trial for the treatment of delayed graft function (DGF) following kidney transplantation and in a Phase 2 trial for the treatment of acute kidney injury (AKI) following open-heart surgery requiring cardiopul

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service